GRO Biosciences

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

 

Our Team

The GRO Biosciences team brings together industry-leading expertise in synthetic biology, protein design, and therapeutic protein development.

 
george_church.png

George Church
Co-founder

George is a pioneering synthetic biologist with foundational contributions to genome sequencing, DNA synthesis, and protein engineering. George led the development of the genomically recoded organisms (GROs) at the core of the GRO Biosciences platform. George is a co-founder and leads the company's Scientific Advisory Board.

andy_ellington.png

Andrew Ellington
Co-founder

Andrew is a field leader on using evolutionary techniques to engineer biopolymers and cells. Andrew led the development of key protein translational machinery to incorporate non-standard amino acids into proteins using GROs. Andrew is a co-founder and member of the company's Scientific Advisory Board. 

dan_mandell.png

Daniel J. Mandell
Chief Executive Officer

Dan is a leading expert in synthetic biology and protein engineering. Together with George Church, he used GROs to produce the first proteins with stability and function dependent on non-standard amino acids.
 

marc_lajoie.jpg

Marc Lajoie
Co-founder and Advisor

Marc led the research effort to produce the first GROs with George Church, laying the foundation for the GRO Biosciences platform. Marc advises the company on genome engineering and design, and protein engineering with non-standard amino acids.

dana_braff.jpg

Dana Braff
Principal Scientist

Dana is a leading innovator in microbial engineering and molecular diagnostics. With Jim Collins at MIT, Dana co-lead the development of programmable genetic circuits that enable a new generation of tools to confront global health crises.

Chris_Gregg.png

Christopher Gregg
Chief Scientific Officer

Christopher developed technologies for multiplexed genome engineering in microbial systems under George Church. Christopher brings leading expertise in genome design and microbial fermentation.
 

ross_thyer.png

Ross Thyer
Co-founder and Advisor

Ross developed protein translational machinery for key non-standard amino acids in GROs to stabilize therapeutic proteins. Ross advises the company on directed evolution, chassis optimization, and biochemical analysis of target therapeutic proteins.

ben_stranges.jpg

Benjamin Stranges
Principal Scientist

Benjamin is an expert in protein biochemistry who led research into polymerase engineering and nanopore sequencing with George Church. Benjamin also brings expertise in protein design and biophysical assays.
 

justin_feng.jpg

Justin Feng
Principal Scientist

Justin is an expert in metabolic engineering and synthetic biology. Together with George Church, Justin used protein engineering to produce the first modular, generalizable approach to monitor the abundance of small molecule metabolites across all domains of life.